The grades of 4 Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an “A” (“strong buy”) or “B” overall (“buy”) rating.
Ligand Pharmaceuticals Incorporated (LGND) improves from a C to a B rating this week. Ligand Pharmaceuticals Incorporated develops drugs which regulate hormone activated intracellular receptors. The company also gets A’s in operating margin growth, earnings surprise, and free cash flow. For more information, get Portfolio Grader’s complete analysis of LGND stock.
This week, Exelixis, Inc.’s (EXEL) ratings are up from a B last week to a A. Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of small-molecule therapeutics for the treatment of cancer and other serious diseases. The company also gets A’s in sales growth, earnings revisions, and earnings surprise. For more information, get Portfolio Grader’s complete analysis of EXEL stock.
ARIAD Pharmaceuticals, Inc. (ARIA) is seeing ratings go up from a C last week to a B this week. ARIAD Pharmaceuticals, Inc. is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. The company also gets A’s in sales growth, earnings revisions, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
This is a strong week for Sophiris Bio Inc. (SPHS). The company’s rating climbs to A from the previous week’s B. The company also gets A’s in earnings revisions. For more information, get Portfolio Grader’s complete analysis of SPHS stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.